JNJ-26854165 is an inhibitor of E3 ligase MDM2 that also indirectly activates p53. This compound exhibits anticancer chemotherapeutic activity, decreasing survival of various cancer cell lines and delaying tumor growth in animal models. JNJ-26854165 also induces S-phase cell cycle arrest and decreases cholesterol efflux and transport in mantle cell lymphoma and multiple myeloma cells.
| Cas No. | 881202-45-5 |
|---|---|
| Purity | ≥98% |
| Formula | C21H20N4 |
| Formula Wt. | 328.42 |
| IUPAC Name | N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine |
| Synonym | Serdemetan |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | J5237 Info Sheet PDF |
|---|
Jones RJ, Gu D, Bjorklund CC, et al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92. Erratum in: J Pharmacol Exp Ther. 2013 Nov;347(2):540. PMID: 23820125.
Chargari C, Leteur C, Angevin E, et al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312(2):209-18. PMID: 21937165.
Kojima K, Burks JK, Arts J, et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010 Sep;9(9):2545-57. PMID: 20736344.
